Literature DB >> 8549361

Epidemiology of quinolone resistance: Europe and North and South America.

F W Goldstein1, J F Acar.   

Abstract

After nearly 10 years of fluoroquinolone usage for a wide range of bacterial infections, a striking difference has been observed in the incidence of bacterial resistance to fluoroquinolones between bacteria responsible for community- and hospital-acquired infections, respectively. Resistance is only rarely encountered among common pathogens. In most studies, 97 to 100% of all pathogens are fully susceptible to fluoroquinolones. In contrast, resistance to fluoroquinolones has emerged and increased among bacteria responsible for nosocomial infections. The incidence of resistance to fluoroquinolones varies between bacterial species, clinical settings and countries, and is related to local epidemic spread of a few clones. The highest incidence of resistance is observed in Pseudomonas aeruginosa, Acinetobacter spp., Serratia marcescens and, particularly, methicillin-resistant Staphylococcus aureus (MRSA): some investigators have reported 95 to 100% fluoroquinolone resistance among MRSA. Follow-up of trends in the resistance to fluoroquinolones based upon surveillance programmes are needed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8549361     DOI: 10.2165/00003495-199500492-00007

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  34 in total

1.  Changes in the sensitivity of urinary pathogens to quinolones between 1987 and 1990 in France.

Authors:  G Aubert; P P Levy; A Ros; R Meley; B Meley; A Bourge; G Dorche
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-05       Impact factor: 3.267

Review 2.  The sleeping giant. Antimicrobial resistance.

Authors:  J M Casellas; M G Blanco; M E Pinto
Journal:  Infect Dis Clin North Am       Date:  1994-03       Impact factor: 5.982

3.  Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis.

Authors:  C Dupeyron; N Mangeney; L Sedrati; B Campillo; P Fouet; G Leluan
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

4.  Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital.

Authors:  I Shalit; S A Berger; A Gorea; H Frimerman
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

5.  Methicillin-resistant Staphylococcus aureus in Europe.

Authors:  A Voss; D Milatovic; C Wallrauch-Schwarz; V T Rosdahl; I Braveny
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-01       Impact factor: 3.267

Review 6.  Comparative activity of the 4-quinolones.

Authors:  I Phillips; A King
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb

7.  The rapid emergence of fluoroquinolone-methicillin-resistant Staphylococcus aureus infections in a community hospital. An in vitro look at alternative antimicrobial agents.

Authors:  K E Aldridge; M S Gelfand; D D Schiro; N L Barg
Journal:  Diagn Microbiol Infect Dis       Date:  1992 Sep-Oct       Impact factor: 2.803

8.  In-vitro activity of ten antimicrobial agents against penicillin-resistant Streptococcus pneumoniae.

Authors:  T J Neal; M A O'Donoghue; E J Ridgway; K D Allen
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

9.  Fluoroquinolone (Lomefloxacin) International Surveillance Trial: a report of 30 months of monitoring in vitro activity.

Authors:  R N Jones
Journal:  Am J Med       Date:  1992-04-06       Impact factor: 4.965

10.  The North American component (the United States and Canada) of an International Comparative MIC trial monitoring ofloxacin resistance.

Authors:  D J Hoban; R N Jones; L J Harrell; M Knudson; D Sewell
Journal:  Diagn Microbiol Infect Dis       Date:  1993 Aug-Sep       Impact factor: 2.803

View more
  16 in total

1.  Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC.

Authors:  F J Schmitz; M E Jones; B Hofmann; B Hansen; S Scheuring; M Lückefahr; A Fluit; J Verhoef; U Hadding; H P Heinz; K Köhrer
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

2.  Optimizing fluoroquinolone utilization in a public hospital: a prospective study of educational intervention.

Authors:  K Lacombe; S Cariou; P Tilleul; G Offenstadt; J L Meynard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-01       Impact factor: 3.267

3.  Multiple novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus.

Authors:  P N Markham; E Westhaus; K Klyachko; M E Johnson; A A Neyfakh
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

4.  Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.

Authors:  S Roychoudhury; C E Catrenich; E J McIntosh; H D McKeever; K M Makin; P M Koenigs; B Ledoussal
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

Review 5.  Fluoroquinolones in paediatrics.

Authors:  D Gendrel; F Moulin
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 6.  Anti-gram-positive agents. What we have and what we would like.

Authors:  R N Grüneberg
Journal:  Drugs       Date:  1997       Impact factor: 9.546

7.  Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli.

Authors:  W V Kern; M Oethinger; A S Jellen-Ritter; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

8.  Molecular surveillance of European quinolone-resistant clinical isolates of Pseudomonas aeruginosa and Acinetobacter spp. using automated ribotyping.

Authors:  S Brisse; D Milatovic; A C Fluit; K Kusters; A Toelstra; J Verhoef; F J Schmitz
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

9.  Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains.

Authors:  M E Jones; M R Visser; M Klootwijk; P Heisig; J Verhoef; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

10.  Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001.

Authors:  K J Christiansen; J M Bell; J D Turnidge; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.